louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02932319: Outpatient Foley Catheter for Induction of Labor in Nulliparous for Prolonged Pregnancy
Official title: Outpatient Foley Catheter for Induction of Labor in Nulliparous for Prolonged Pregnancy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Induction of Labour
Prolonged Pregnancy
Keywords: induction of labour
nulliparous
prolonged pregnancy
foley catheter
vaginal birth
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2016-10-13
Enrollment: 43
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 15 to 20 % of nulliparous needs an induction at term. None study has evaluated Foley catheter induction at home versus expectative in this population


Eligibility criteria: Inclusion Criteria:

* prolonged pregnancy (D+4) nulliparous no complication during pregnancy location near th hospital (20 mn by car) Bishop \< 6

Exclusion Criteria:

* medical history small for gestationnal age PROM Live alone

Primary outcomes:
measure: Bishop score
timeFrame: at term birth +5 days
Secondary outcomes:
measure: Labour ward
timeFrame: at term birth +5 days
measure: Total dose of prostaglandin used in case of cervical ripening.
timeFrame: During labor
measure: Utilization rate of oxytocin
timeFrame: During labor
measure: Total dose of Ocytocin used or not for induction labor
timeFrame: During labor
measure: number of birth
timeFrame: between the term consultation + 4 days (randomization) and delivery time
measure: delivery rate
timeFrame: within 24 hours and 48 hours after randomization
measure: Caesarean rate
timeFrame: before labor and during labor
measure: Maternal complications
timeFrame: through study completion, at 4 day
measure: Fetal complications
timeFrame: through study completion, at 4 day
measure: Neonatal complications
timeFrame: through study completion, at 4 day
measure: Duration of hospital stay
timeFrame: through study completion, at 4 day
Other outcomes:
Locations:
city: Caen
country: France
facility: CHU de Caen
city: Lille
country: France
facility: Hôpital Jeanne de Flandre - CHRU
city: Roubaix
country: France
facility: CH Roubaix
city: Rouen
country: France
facility: CHU Rouen
city: Valenciennes
country: France
facility: Ch Valenciennes
Study officials:
affiliation: University Hospital, Lille
name: Charles Garabedian, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01519219: Assessment Of Liver Function in Patients Undergoing Hepatic Irradiation
Official title: Assessment Of Liver Function in Patients Undergoing Hepatic Irradiation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatic Irradiation
Keywords: hepatic irradiation
IC-GREEN
Lead sponsor: University of Michigan Rogel Cancer Center
Sponsor class: OTHER
First posted: 2012-01-26
Enrollment: 208
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who take part in this study are required to be scheduled for hepatic irradiation.

Brief summary: The goal of the trial is to assess the effect of radiation treatment on liver function as determined by indocyanine green extraction. The long term goal is to determine if individual assessment of liver function using the IC-Green method, either alone or in combination with other factors, will provide Radiation Induced Liver Disease (RILD) risk-estimates that are superior to the probabilistic method currently in use.

Detailed description: Following intravenous injection, IC-GREEN is rapidly bound to plasma protein, of which albumin is the principle carrier (95%). IC-GREEN is taken up from the plasma almost exclusively by the hepatic parenchymal cells and is secreted entirely into the bile. It undergoes no significant extrahepatic or enterohepatic circulation. Simultaneous arterial and venous blood estimations have shown negligible renal, peripheral, lung or cerebro-spinal uptake of the dye. Therefore, the serum clearance rate (determined from serial serum concentration measurements at various times after intravenous injection) can serve as a useful index of liver function.

Eligibility criteria: Inclusion Criteria:

* 18 or older, all gender, ethnicities and races
* Life expectancy of at least 12 weeks
* Zubrod performance status ≤ 2
* Baseline clinical assessments of liver function by complete history and physical examination
* Laboratory tests to be done within 6 weeks prior to start of radiation: CBC and platelets, liver function tests including SGOT, SGPT, Alkaline Phosphatase, and bilirubin, albumin, BUN, creatinine, PT/PTT, INR

Exclusion Criteria:

* Pregnant
* History of allergy or are sensitive to IC-Green, iodine or to radiographic media

Primary outcomes:
measure: Baseline IC-GREEN elimination
timeFrame: 1 day
Secondary outcomes:
measure: Change in IC-green elimination after radiation therapy
timeFrame: 6 months
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Comprehensive Cancer Center
state: Michigan
Study officials:
affiliation: University of Michigan Rogel Cancer Center
name: Theodore Lawrence, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00626119: Vibro-Acoustography Imaging in Finding Breast Microcalcifications and Lesions in Women
Official title: In Vivo Breast Imaging by Vibro-acoustography
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: breast cancer
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2008-02-29
Enrollment: 34
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with and without breast masses

Brief summary: RATIONALE: New diagnostic procedures, such as vibro-acoustography imaging, may be an effective method of finding microcalcifications and lesions in the breast.

PURPOSE: This clinical trial is studying how well vibro-acoustography imaging works in finding breast microcalcifications and lesions in women.

Detailed description: OBJECTIVES:

* To further develop a new method of in vivo imaging of the breast using vibro-acoustography (VA) imaging.
* To demonstrate and evaluate the capability of VA imaging in detecting microcalcifications and lesions inside the human breast.

OUTLINE: Participants undergo vibro-acoustography (VA) imaging of the breast using ultrasonography over 90 minutes. Participants may also undergo further imaging using clinical ultrasonography.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Meets one of the following criteria:

  * Healthy participant
  * Proven microcalcifications and/or lesions in the breast
* Hormone status not specified

PATIENT CHARACTERISTICS:

* Female
* Menopausal status not specified
* Not pregnant or nursing
* No condition that does not allow proper use of study imaging devices

PRIOR CONCURRENT THERAPY:

* Not specified

Primary outcomes:
measure: Further development of a new method of in vivo imaging of the breast using vibro-acoustography (VA) imaging
timeFrame: one day
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic Cancer Center
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Mostafa Fatemi, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00059319: Reduced Manipulation of the Aorta and Neurobehavioral Outcome Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Coronary Disease
Keywords: coronary artery bypass graft surgery
CABG surgery
neurobehavioral impairment
aorta clamping
aorta manipulation
microemboli
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Sponsor class: NIH
First posted: 2003-04-24
Enrollment: 300
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to determine whether aortic manipulation in patients undergoing coronary bypass graft surgery leads to increased incidence of microemboli and subsequent impairment of neurobehavioral function.

Detailed description: Patients who have coronary artery bypass graft (CABG) surgery must have their aorta (the large blood vessel that is attached to the heart) clamped with an instrument. There are two basic ways of manipulating the aorta during surgery. One way is to place a single clamp across the aorta. The other way is to place more than one clamp on the aorta in several places. Both methods are used, but it is not known if one way is better than the other.

The purpose of this study is to compare the two methods of clamping to see if one way is better than the other, and to determine whether patients who undergo reduced manipulation of the aorta have fewer microemboli delivered to the brain during CABG surgery and have a lower incidence of neurobehavioral problems following surgery. Microemboli are tiny fat particles that enter the bloodstream during surgery, circulate to the brain, and block tiny blood vessels, causing brain deficits.

Participants in this trial will be randomly classified into one of two groups: the experimental group will undergo cross clamping of the aorta with a single clamp and be given retrograde cardioplegia for heart protection, and the control group will undergo cross clamping of the aorta with multiple clamps and be given antegrade cardioplegia for heart protection. Neurobehavioral assessments will be accomplished with a comprehensive battery of neurological and neuropsychological tests.

Eligibility criteria: * Participants must be English-speaking patients,
* 50 years of age or older, and
* undergoing elective CABG surgery.
* Participants of both genders and all races are eligible.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Winston Salem
country: United States
facility: Wake Forest University Baptist Medical Center
state: North Carolina
Study officials:
affiliation: Wake Forest University Health Sciences
name: John W. Hammon, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06420219: An Integrative Multi-Omic Characterization of Head and Neck Carcinogenesis, Progression and Recurrence
Official title: An Integrative Multi-Omic Characterization of Head and Neck Carcinogenesis, Progression and Recurrence
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Head and Neck Carcinoma
Lead sponsor: University of Southern California
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2024-05-17
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with a new diagnosis of head and neck cancer

Brief summary: This study evaluates the cell and biomarkers associated with the aggressive behavior of cancer.

Detailed description: PRIMARY OBJECTIVE:

I. High-resolution single-cell profiling of Cancer-associated fibroblasts (CAFs) in Human papillomavirus (HPV)+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) and metastatic lymph nodes.

OUTLINE: This is an observational study.

Patients undergo photography, blood sample collection, tissue collection and have their medical records reviewed on study.

Eligibility criteria: Inclusion Criteria:

* Diagnosis/disease status: New diagnosis of head and neck cancer
* Allowable type and amount of prior therapy: No prior treatment
* Age ≥ 18 years.
* Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

* Patients who have had treatment of head and neck cancer

Primary outcomes:
measure: Overall survival
timeFrame: Up to 5 years
measure: Disease free survival
timeFrame: Up to 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: USC / Norris Comprehensive Cancer Center
state: California
Study officials:
affiliation: University of Southern California
name: Albert Y Han, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06330519: Enhancing Anaesthetic Success in Mandibular Molars With Symptomatic Irreversible Pulpitis: A Comparative Randomized Controlled Trial
Official title: "Impact of Different Techniques on the Efficacy of Anaesthesia in Mandibular Molars With Acute Irreversible Pulpitis: A Randomized Controlled Trial"
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pulpitis - Irreversible
Keywords: dexamethasone
intraligamentary
cryotherapy
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2024-03-26
Enrollment: 188
Sex: ALL
Minimum age (years): 25
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of this clinical trial is to assess the effect of

* Preoperative intraligamentary corticosteroids injection
* Cryotherapy which is cold application on :

  * Hard tooth structure ( crown of the tooth )
  * Soft tissue overlying roots on the efficacy of the inferior alveolar nerve block anaesthesia in patients with mandibular molars with symptomatic irreversible pulpitis. The main question it aims to answer are: • Does intraligamentary dexamethazone injection increase the success rate of inferior alveolar nerve block without the need for oral premedication.

Participants will describe their preoperative pain level to the investigator and describe their pain level during the treatment.

Researchers will compare cryotherapy to see if it increases the success rate of inferior alveolar nerve block.


Eligibility criteria: Inclusion Criteria:

* Participants willing to commit for the entire period of the trial and agreed to sign the written consent after full explanation of the study.
* Having a mandibular molar tooth diagnosed with symptomatic irreversible pulpitis (hot tooth - vital pulp, intermittent or continuous sharp pain that lasts longer after removal of the stimulus).

Exclusion Criteria:

* Presence of any systemic disease or allergic reactions.
* Vulnerable group; prisoners, pregnant females, mentally ill, etc...
* The presence of a periapical radiolucency.
* Teeth with open apices.
* A previous root canal treatment.
* Sinus tracts.
* Local gum swelling around the affected tooth.
* Severe periodontal disease .
* Presence of periodontal pockets \>3 mm in the affected tooth.
* Absence of bleeding in the pulp chamber on access cavity preparation.
* Patients with doubted diagnosis due to multiple carious teeth.

Primary outcomes:
measure: The effect of intraligamentary dexamethazone injection on the success rate of inferior alveolar nerve block
timeFrame: Assessed up to 30 minutes, from lip numbness point until the end of pulp extirpation.
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University
Study officials:
References:
Clinical trial NCT05986019: Transcranial Focused Ultrasound (tFUS) Modulation of Reward Network
Official title: Evaluating the Effects of Transcranial Focused Ultrasound (tFUS) on Fronto-striatal Resting State Functional Connectivity in Healthy Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
First posted: 2023-08-14
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Active or Sham tFUS
Primary purpose: BASIC_SCIENCE

Brief summary: Aim: Evaluate whether sonicating the Nucleus Accumbens (NAc) with transcranial focused ultrasound modifies functional connectivity between the NAc and the prefrontal cortex (PFC).

In this single visit, open-label pilot trial, we plan to evaluate whether transcranial focused ultrasound (tFUS), delivered to the nucleus accumbens (NAc) within the magnetic resonance imaging (MRI) scanner will impact resting state functional connectivity between the NAc and functionally connected brain regions like the prefrontal cortex (PFC) and the anterior cingulate cortex (ACC) in up to 10 healthy individuals.

HYPOTHESIS : tFUS will reduce prefrontal cortex (PFC)-NAc functional connectivity, in healthy individuals. We will investigate this hypothesis by administering tFUS within to MRI scanner to healthy individuals and conduct resting state functional neuroimaging before- and after the tFUS stimulation.


Eligibility criteria: Inclusion Criteria:

* Age 18-65
* Have the capacity and ability to provide one's own consent and sign the informed consent document

Exclusion Criteria:

* Contraindicated for MRI.
* Any current or recent untreated medical, neurological, or psychiatric conditions
* Metal implant devices in the head, heart, or neck.
* History of brain surgery.
* History of myocardial infarction or arrhythmia, bradycardia.
* Personal or family history of seizure or epilepsy or personal use of medications that substantially reduce seizure threshold (e.g., olanzapine, chlorpromazine, lithium).
* Personal history of head injury, concussion, or self-report of moderate to severe traumatic brain injury.
* Individuals suffering from frequent/severe headaches.
* Individuals with a reported history of psychosis or mania, or individuals who are actively manic or psychotic.
* Regular or recent pain medication use
* Moderate to severe alcohol use (\>3 drinks/day) or illicit substance use (urine confirmed).
* Persons who are pregnant or lactating

Primary outcomes:
measure: Resting State Functional Connectivity
timeFrame: 24 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Charleston
country: United States
facility: Medical University of South Carolina Institute of Psychiatry
state: South Carolina
Study officials:
References:
Clinical trial NCT00994019: Study of Oral Papillomavirus In Teens and Twenties
Official title: Short-term Natural History of Oral HPV Infection Among Young Adults
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: STD
Keywords: HPV
oral cancer
young adults
Lead sponsor: Johns Hopkins Bloomberg School of Public Health
Sponsor class: OTHER
First posted: 2009-10-14
Enrollment: 550
Sex: ALL
Minimum age (years): 18
Maximum age (years): 26
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: High risk young adults

Brief summary: Recently human papillomavirus (HPV) has been recognized to cause some oropharyngeal (tonsil) cancer. But very little is known about oral HPV infection and risk factors. This study will evaluate how common oral HPV infection is, what sexual behaviors are associated with risk for infection, and how long infections tend to last.

Detailed description: 18-25 year old individuals are being recruited from STD clinics in Baltimore County and followed every three months for this study.

Eligibility criteria: Inclusion Criteria:

* Age 18 -26 years

Exclusion Criteria:

* Never received HPV vaccine (Gardasil or Cervarix)

Primary outcomes:
measure: Oral HPV infection
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Baltimore County Woodlawn Health Centers
state: Maryland
city: Baltimore
country: United States
facility: Baltimore County Eastern Health Center
state: Maryland
Study officials:
affiliation: Johns Hopkins Bloomberg School of Public Health
name: Gypsyamber D'Souza, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: D'Souza G, Wentz A, Kluz N, Zhang Y, Sugar E, Youngfellow RM, Guo Y, Xiao W, Gillison ML. Sex Differences in Risk Factors and Natural History of Oral Human Papillomavirus Infection. J Infect Dis. 2016 Jun 15;213(12):1893-6. doi: 10.1093/infdis/jiw063. Epub 2016 Feb 10.
citation: D'Souza G, Kluz N, Wentz A, Youngfellow RM, Griffioen A, Stammer E, Guo Y, Xiao W, Gillison ML. Oral Human Papillomavirus (HPV) Infection among Unvaccinated High-Risk Young Adults. Cancers (Basel). 2014 Aug 14;6(3):1691-704. doi: 10.3390/cancers6031691.
Clinical trial NCT03379519: Protocol of Multi-domain Attention Training
Official title: The Development and Evaluation of Multi-domain Attention Training for Older Adults With Mild Cognitive Impairment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mild Cognitive Impairment
Lead sponsor: Ministry of Science and Technology, Taiwan
Sponsor class: OTHER_GOV
First posted: 2017-12-20
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study sought to investigate the changes in attention in older adults with mild cognitive impairment after Multi-domain Attention Training .

Detailed description: This double-blind randomized controlled study has a 2-arm parallel group design. All subjects will be randomized by the block randomization, into intervention group (Multi-domain Attention Training, MAT), or active control group (Passive information activities, PIA). Training sessions of the MAT group are 45 minutes/day, 3 days/week, for 12 weeks (36 sessions each). The training of PIA group is the same as MAT group. The investigators constructed a rigorous MAT program adhering to the Consolidated Standards of Reporting Trials (CONSORT) reporting guidelines. The investigators expect to determine the improvement in attention function of older adults with mild cognitive impairment after using the MAT program.

Eligibility criteria: Inclusion Criteria:

* Participants must endorse at least two items from a list of frequent subjective memory complaints by patient and/or an informant
* Objective memory impairment on neuropsychological tests of memory 1.5 SD or more below age/education norms
* Clinical neurologic examination by the Mini-Mental State Examination (MMSE) score of 24 or higher
* No impairment in personal activities of daily living (P-ADL) as determined by clinical interview with participant and family

Exclusion Criteria:

* The clinical diagnosis of dementia was based on the DSM-IV-TR
* Active in another cognitive or memory-related training in the past year
* Comorbid medical conditions that would predispose them to imminent functional decline or cognitive impairment
* A diagnosis of major neurological or psychiatric illness history and/or behavioral problems that would sufficiently impair performance to make participation impossible
* Severe losses in vision, hearing, or communicative ability

Primary outcomes:
measure: Change in attention as measured by the Digit Span Task (DS).
timeFrame: Change from baseline in executive attention at Immediate post-test, 3 months, 6 months after intervention.
Secondary outcomes:
measure: Change in attention as measured by the Trail Making Test (TMT).
timeFrame: Change from baseline in spatial orienting attention at Immediate post-test, 3 months, 6 months after intervention.
Other outcomes:
Locations:
Study officials:
References: